Each 5 mL (1 teaspoonful) contains: Cefpodoxime (as proxetil) 50 mg.
Each film-coated tablet contains: Cefpodoxime (as proxetil) 100 mg.
Cefpodoxime proxetil is a bactericidal antibiotic and is stable to hydrolysis by many beta-lactamases. It has a mode of action and spectrum of activity similar to those of the third-generation antibiotics. Cefpodoxime also has some activity against Staphylococcus aureus, and may be more active than cefixime against penicillin-resistant strains of Streptococcus pneumoniae.
Pharmacology: Pharmacokinetics: Cefpodoxime proxetil is de-esterified in the intestinal epithelium following oral administration, to release active cefpodoxime in the blood stream. Bioavailability is about 50% in fasting subjects and may be increased in the presence of food. Absorption is decreased in conditions for low gastric acidity. Plasma concentrations of about 1.5, 2.5 and 4.0 ug per mL have been achieved 2 to 3 hours after oral doses of 100, 200 and 400 mg cefpodoxime respectively. About 20 to 30% of cefpodoxime is bound to plasma proteins. The plasma half-life is about 2 to 3 hours and is prolonged in patients with impaired renal function.
Cefpodoxime reaches therapeutic concentrations in the respiratory and genito-urinary tracts and bile. It has been detected in low concentrations in breast milk.
Cefpodoxime is excreted unchanged in the urine. Some is removed by dialysis. Absorption may be enhanced if Cefpodoxime proxetil is given with food.
Cefpodoxime proxetil is used for the treatment of susceptible infections including gonorrhea, otitis media, lower respiratory tract infections and urinary tract infections.
Adult: Respiratory and Urinary Tract Infections: Usual dose is 100 mg to 200 mg every 12 hours or as prescribed by the physician.
Skin Infections: 200 mg to 400 mg every 12 hours or as prescribed by the physician.
Uncomplicated Gonorrhea: Single dose of 200 mg may be given or as prescribed by the physician.
Children: Respiratory Tract Infections: Doses of 8 mg to 10 mg per kg body-weight daily may be given in two divided doses, up to a maximum of 200 mg daily or as prescribed by the physician.
Otitis Media: 400 mg daily or as prescribed by the physician.
The interval between doses should be extended in patients with severe renal impairment.
Cefpodoxime should not be given to patients who are hypersensitive to it or to other cephalosporins.
Cefpodoxime should also be given with care to patients with renal impairment; a dosage reduction may be necessary.
The most frequently reported adverse effects of cefpodoxime are gastrointestinal disturbances, especially diarrhea.
Absorption of cefpodoxime is decreased by concurrent ingestion of antacids or histamine H2-receptor antagonists. Probenecid reduces the renal excretion of cefpodoxime.
Direction for Reconstitution: To make 60 mL reconstituted suspension, add approximately 40 mL of water. Shake well until the granules are evenly suspended. The suspension is stable for one week at temperatures not exceeding 30°C and two weeks under refrigeration (2-8°C).
Store at temperatures not exceeding 30°C.
J01DD13 - cefpodoxime ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
FC tab 100 mg x 100's. Granules for oral susp 50 mg/5 mL x 60 mL.